Xultophy 100/3.6 Drug Interactions: 3 Major, 618 Moderate
Xultophy 100/3.6 (Insulin Degludec And Liraglutide) Drug Interactions
Check all documented drug-to-drug interactions. Major, moderate, and minor interactions with descriptions.
A therapy excluded from this list does not necessarily mean no interaction exists between that therapy and Xultophy 100/3.6. Always confirm against the full prescribing information.
100 interactions
Acarbose
The risk or severity of hypoglycemia can be increased when Acarbose is combined with Insulin degludec.
Level 1 evidence
Acarbose
The risk or severity of hypoglycemia can be increased when Acarbose is combined with Liraglutide.
Level 2 evidence
Acebutolol
The therapeutic efficacy of Insulin degludec can be increased when used in combination with Acebutolol.
Level 1 evidence
Acebutolol
The therapeutic efficacy of Liraglutide can be increased when used in combination with Acebutolol.
Level 1 evidence
Acetazolamide
The risk or severity of hypoglycemia can be increased when Acetazolamide is combined with Insulin degludec.
Level 1 evidence
Acetyl sulfisoxazole
The risk or severity of hypoglycemia can be increased when Acetyl sulfisoxazole is combined with Insulin degludec.
Level 1 evidence
Acetylsalicylic acid
The risk or severity of hypoglycemia can be increased when Acetylsalicylic acid is combined with Liraglutide.
Level 1 evidence
Acetylsalicylic acid
The risk or severity of hypoglycemia can be increased when Acetylsalicylic acid is combined with Insulin degludec.
Level 1 evidence
Albuterol
The therapeutic efficacy of Insulin degludec can be decreased when used in combination with Salbutamol.
Level 1 evidence
Alclometasone
The risk or severity of hyperglycemia can be increased when Alclometasone is combined with Liraglutide.
Level 1 evidence
Alclometasone
The risk or severity of hyperglycemia can be increased when Alclometasone is combined with Insulin degludec.
Level 1 evidence
Alogliptin
The risk or severity of hypoglycemia can be increased when Liraglutide is combined with Alogliptin.
Level 2 evidence
Alogliptin
The risk or severity of hypoglycemia can be increased when Alogliptin is combined with Insulin degludec.
Xultophy 100/3.6 (Insulin Degludec And Liraglutide) has 1039 documented drug interactions. Always review the full list with a pharmacist before co-prescribing.
Xultophy 100/3.6 (Insulin Degludec And Liraglutide) has 3 major, 618 moderate, and 418 minor documented interactions.
A therapy excluded from this list does not necessarily mean no interaction exists between that therapy and Xultophy 100/3.6. Always confirm against the full prescribing information.